Dicot Pharma

Dicot Pharma has received a new patent approved in the US that protects key steps in the manufacture of LIB-01 and is valid until 2042. Dicot Pharma has previously received a  Notice of Allowance for a total of three patent applications in the US, and this is the first of these to be formally approved.

"It is of course a great success that we now obtain this important patent protection for the key market USA and we are now working on the corresponding application for other markets," says CEO Elin Trampe.